根据修订版IPSET血栓分层评估一线羟基脲治疗反应对原发性血小板增多症的预后价值
在西班牙原发性血小板增多症登记研究的1080例患者中,按修订版IPSET血栓分层评估羟基脲一线治疗后的完全血液学反应(CHR)及耐药/不耐受的预后价值。中位治疗5年,CHR率67%,耐药/不耐受率20%;高危患者达CHR与动脉血栓风险降低相关(HR 0.35),中危和高危患者达CHR者生存更长、骨髓纤维化发生率更低;耐药/不耐受与骨髓纤维化概率升高相关,但对生存或血栓风险无影响。
要点
- 中位治疗5年,CHR率67%,耐药/不耐受率20%(5年概率13%)。
- 高危患者达CHR者动脉血栓风险降低(HR 0.35,95%CI 0.2-0.6,p=0.001)。
- 中危和高危患者达CHR者生存更长、骨髓纤维化发生率更低。
核心结论
- 羟基脲治疗中达到完全血液学反应与更好的结局相关,可能作为选择二线临床试验候选者的早期指标。
研究设计与样本
- 来自西班牙原发性血小板增多症登记研究的1080例患者,按修订版IPSET血栓分层分为极低危61例、低危83例、中危261例和高危675例。
主要发现
- 中位治疗持续时间5年,720例(67%)患者记录到完全血液学反应,1年概率51%;219例(20%)患者出现耐药/不耐受,5年概率13%。
- 校正其他危险因素后,高危患者达到完全血液学反应者动脉血栓风险降低(HR 0.35,95%CI 0.2-0.6,p=0.001),静脉血栓风险有降低趋势(HR 0.45,95%CI 0.2-1.02,p=0.06),而中危或低危患者未观察到相关性。
- 与无反应者相比,达到完全血液学反应的中危和高危患者生存更长、骨髓纤维化发生率更低。
- 出现羟基脲耐药/不耐受(主要为血细胞减少)与骨髓纤维化概率升高相关,但未证实对生存或血栓风险有影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hydroxyurea (HU) constitutes the first-line treatment in most patients with essential thrombocythemia (ET), but criteria for changing therapy are not clearly established. The prognostic value of complete hematological response (CHR) and resistance/intolerance to HU was assessed in 1080 patients from the Spanish Registry of ET, classified according to revised IPSET-Thrombosis stratification (Very low- n = 61, Low- n = 83, Intermediate- n = 261, and High-risk n = 675). With a median therapy duration of 5 years, CHR was registered in 720 (67%) patients (1-year probability 51%) and resistance/intolerance in 219 (20%) patients (5-years probability 13%). After correction by other risk factors, High-risk patients achieving CHR showed a reduced risk of arterial thrombosis (HR: 0.35, 95%CI: 0.2-0.6, p = 0.001) and a trend towards lower risk of venous thrombosis (HR: 0.45, 95%CI: 0.2-1.02, p = 0.06) whereas no association was observed for intermediate- or low-risk patients. In comparison with non-responders, intermediate- and high-risk patients achieving CHR had longer survival and lower myelofibrosis incidence. Development of resistance/intolerance to HU, mainly cytopenia, was associated with higher probability of myelofibrosis but no effect on survival or thrombotic risk was demonstrated. In conclusion, CHR with HU is associated with better outcomes and might be an early indicator for selecting candidates to second-line clinical trials.
引用
- Santaliestra M, Garrote M, Noya MS, et al. Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia. Leukemia. 2024. PMID: 39333760. doi:10.1038/s41375-024-02416-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。